#USA #Milford #Waters Corporation #Mass Spectrometry #Cyclic IMS

Waters Unveils the Cyclic IMS P20 Mass Spectrometer

On June 1, 2026, Waters Corporation, a global leader in analytical technologies, introduced the Cyclic IMS P20 Mass Spectrometer during the 74th ASMS Conference on Mass Spectrometry and Allied Topics. This innovative device represents a significant leap in structural and spatial omics, enabling scientists to unlock subtle biological differences previously unseen. With its capabilities, the P20 Mass Spectrometer aims to revolutionize early disease detection and advance the development of next-generation biotherapeutics.

Key Features and Capabilities

The Cyclic IMS P20 combines multipass Cyclic Ion Mobility Spectrometry with a comprehensive suite of fragmentation, probing, and imaging processes. Features include:

• - A more than 10-fold increase in MS/MS sensitivity compared to earlier models.
• - An extended upper mass range by 50% to over 100 kDa.
• - Additional structural probing methods such as tandem ion mobility spectrometry (IMSn), electron-capture dissociation (ECD), surface-induced dissociation (SID), and collision-induced unfolding (CIU).

This product efficiently addresses the challenges faced by researchers who require higher sensitivity and structural resolution when studying larger and more complex therapeutic targets.

Enhanced Sensitivity and Visualization

James Hallam, the Vice President and General Manager of Liquid Chromatography-Mass Spectrometry at Waters, remarked, "Advanced tools for structural and spatial omics are critical for medical progress. The Cyclic IMS P20 MS offers unprecedented insights into molecular nuances that influence disease mechanisms. We foresee advancing next-generation discoveries with this technology."

Research laboratories, like that led by Dr. Kostas Thalassinos at University College London, have endorsed the device's capabilities. Dr. Thalassinos emphasizes that this Mass Spectrometer allows for intricate analysis of proteins connected to diseases like Type II diabetes and drastically enhances the sensitivity of detecting low-abundance species crucial for understanding disease pathology.

Cutting-edge Imaging Techniques

Moreover, the Cyclic IMS P20 features integrated MALDI (Matrix-Assisted Laser Desorption/Ionization) and DESI (Desorption Electrospray Ionization) imaging techniques. This unique combination aids researchers in observing molecules directly within their biological samples with unprecedented clarity. Additionally, the system's multi-dimensional analytic approach enhances our understanding of the connections between molecular structures and their respective tissue microenvironments.

This capability not only improves biomarker identification but also supports lipidomics, drug localization studies, and further complex biological experiments.

Availability and Future Prospects

The Cyclic IMS P20 Mass Spectrometer will be featured at the ASMS 2026 conference and is expected to be available for global distribution starting September 2026. Researchers eager to explore its capabilities can visit Waters’ official product page or request a demo to witness firsthand how this equipment can enhance their analytical workflows.

With a commitment to advancing life sciences, Waters Corporation focuses on pioneering science and innovation, striving to improve health outcomes globally. This cutting-edge instrument underscores their dedication to facilitating breakthroughs that can positively impact patient care and therapeutic development.

For more detailed information on the Cyclic IMS P20 Mass Spectrometer, please visit the Waters Corporation's official website or explore the product page.

---

Waters Corporation is listed on the NYSE with the ticker WAT. As a vital entity in the analytical technology sector, the company continues to enhance its portfolio and leverage scientific expertise for extraordinary advancements in healthcare and diagnostics.